12 March 2024: Original Paper
Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians
Alexander Wiseman 1ADEF* , Tarek Alhamad 2DE , Rita R. Alloway 3DEF , Beatrice P. Concepcion 4DE , Matthew Cooper 5DE , Richard Formica 6DE , Christina L. Klein 7DE , Vineeta Kumar 8DEF , Nicolae Leca 9DE , Fuad Shihab 10DE , David J. Taber 11DE , Sarah Mulnick 12ABCDE , Donald M. Bushnell 12BCDE , Monica Hadi 13ABCDE , Suphamai Bunnapradist 14ADEFDOI: 10.12659/AOT.943498
Ann Transplant 2024; 29:e943498
Table 4 Delphi statement progression, LCPT (Envarsus XR®) use in a conversion setting.
| Original statement for consensus* | Status Round 1 | Action Round 2 | Final statusa | Final consensus | Final statement* |
|---|---|---|---|---|---|
| 16. Patients should consistently take Envarsus XR on an empty stomach, rather than consistently with or without food | Consensus | Consensus after R1 | 92% | Patients should consistently take Envarsus XR on an empty stomach, rather than consistently with or without food | |
| 17. When available, pharmacogenomic screening is recommended for initial dosing considerations for Envarsus XR for all patients | No consensus | Merged with Statement 18 | No consensus in R1, merged after R1 to create Statement 20 | ||
| 18. When available, pharmacogenomic screening is recommended for initial dosing considerations for Envarsus XR only for specific patient populations | No consensus | Merged with Statement 17 | No consensus in R1, merged after R1 to create Statement 20 | ||
| 19. Trough level assessment of Envarsus XR should take into account the time to achieve steady state (approximately 7 days) | Consensus | Consensus after R1 | 100% | Trough level assessment of Envarsus XR should take into account the time to achieve steady state (approximately 7 days) | |
| 20. | N/A | Statements 17 and 18 were combined in Round 2 | Consensus after R2 | 83% | |
| 21. Additional cost and formulary considerations pose barriers to the use of Envarsus XR as first line therapy in the de novo setting | Consensus | Consensus after R1 | 75% | Additional cost and formulary considerations pose barriers to the use of Envarsus XR as first line therapy in the de novo setting | |
| 22. Additional costs and staff time required pose barriers to conversion to Envarsus XR | Consensus | Consensus after R1 | 91% | Additional costs and staff time required pose barriers to conversion to Envarsus XR | |
| 23. There are no specific recommendations for utilization of Envarsus XR related to intrapatient variability, | No consensus | Statement revised for consensus in Round 2 | Consensus after R2 | 83% | . There are no specific recommendations for utilization of Envarsus XR related to intrapatient variability |
| 3. Further evidence of clinical long-term outcomes (graft survival, renal function) support the use of Envarsus XR current clinical practice, in both the de novo setting and conversion setting | No consensus | Statement revised for consensus in Round 2 | Consensus after R2 | 92% | Further evidence of clinical long-term outcomes (graft survival, renal function) support the use of Envarsus XR current clinical practice, in both the de novo setting and conversion setting |
| a Consensus was set at ≥75% (at least 9 of the 12 panelists). Final consensus was agreed by all 12 panelists. * in an original statement for consensus indicates wording that has been altered or deleted. in a final statement indicates wording that has been altered or added. | |||||